Ansell D, et al.
Chronic renal failure in kidney transplant recipients.
*Am J Transplant* 2007;7:1167–1176.......................................................... 37

Bakker SJ, et al.
Metabolic syndrome: a fate morgana.

Bjorneklett R, et al.
Long-term risk of cancer in membranous nephropathy patients.

Block GA, et al.
Mortality effect of coronary calcification and phosphorus binder choice in incident hemodialysis patients.
*Kidney Int* 2007;71:438–441................................................................. 27

Brantma AH, et al.
What predicts progression and regression of urinary albumin excretion in the non-diabetic population?

Cunningham J.
Pathogenesis and prevention of bone loss in patients who have kidney disease and receive long-term immunosuppression.

Cupisti A, et al.
Soy protein diet improves endothelial dysfunction in renal transplant patients.

Eprodisate for the treatment of renal disease in AA amyloidosis.

Éthier J, et al.
Aspirin prescription and outcomes in hemodialysis patients: the Dialysis Outcomes and Practices Patterns Study (DOPPS).

Feng JX, et al.
Restricted intake of dietary advanced glycation end products retards renal progression in the remnant kidney model.

Fiser D, et al.
Fibroblast growth factor-23 (FGF23) predicts progression of chronic kidney diseases. The Mild to Moderate Kidney Disease (MMD) Study.

Frois U, et al.
Prospective age-matching in elderly kidney transplant recipients—a 5-year analysis of the Eurotransplant Senior Program.
*Am J Transplant* 2007; Oct 31, in press......................................................... 91

Gera M, et al.
Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosuppression.

Goldsmith D, et al.
Anaemia after renal transplantation – role of immunosuppressive drugs and a pathophysiologically appraisal.
*Nephrol Dial Transplant* 2006;21:49–574....................................................... 19

Grudzinski L, et al.
Sodium citrate 4% locking solution for central venous dialysis catheters–an effective, more cost-efficient alternative to heparin.

Hagivara S, et al.
High incidence of renal failure in patients with aortic aneurysm.

Hamre RA, et al.
Polycystic kidney disease is a risk factor for new-onset diabetes after transplantation.
*Transplantation* 2007;83:36–40................................................................. 11

Himmelfarb J, et al.
Acute kidney injury: changing lexigraphic, definitions and epidemiology.
*Kidney Int* 2007;71:971–976................................................................. 72

Hutchison CA, et al.
National survey of heparin-induced thrombocytopenia in the haemodialysis population of the UK population.

Cho ME, et al.
Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis.

Chonchol M, et al.
Simvastatin for the secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency.

Imbasciati E, et al.
Pregnancy in CRD stages 3 to 5: fetal and maternal outcomes.

Jones-Burton C, et al.
Urinary cotinine as an objective measure of cigarette smoking in chronic kidney disease.

Kayes GA.
Disorders in high – density metabolism with insulin resistance and chronic kidney disease.
*J Ren Nutr* 2007;17:1–4-8........................................................................ 89

KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for diabetes and Chronic Kidney Disease.

Kent PS.
Issues of obesity after kidney transplantation.
*J Ren Nutr* 2007;17:107–113................................................................. 55

Kilpatrick RD, et al.
Association between serum lipids and survival in hemodialysis patients and impact of race.

Korantzopoulos P, et al.
Multifactorial intervention in metabolic syndrome targeting at prevention of chronic kidney disease – ready for prime time?
Lam MF, et al.
Hyperleptinaemia and chronic inflammation after peritonitis predicts poor nutritional status and mortality in patients on peritoneal dialysis.

Le Moer Y, et al.
Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation.
*Am J Transplant* 2007;7:2494–2503 ..........................................................  77

Mancini E, et al.
Prevention of dialysis hypotension episodes using logic control system.

Mehrotra R, et al.
Chronic peritoneal dialysis in the United States: declining utilisation despite improving outcomes.

Nankivell BJ, et al.
Increased vascular resistance and not salt retention characterized Cyclosporine A-induced hypertension: Report in an anuric patient.
*Am J Transplant* 2007;7:2042–2046 ..................................................  63

Napier J, et al.
A prospective national study of acute renal failure treated with RRT: incidence, etiology and outcomes.
*Nephrol Dial Transplant* 2007;22:2513–2519 ..................................................  70

Perkins BA, et al.
Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes.

Praga M, et al.
Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes.

Suliman ME, et al.
Increased vascular resistance and not salt retention characterized Cyclosporine A-induced hypertension: Report in an anuric patient.
*Am J Transplant* 2007;7:2042–2046 ..................................................  63

Swaminathan S, et al.
New insights into nephrogenic systemic fibrosis.

Wahba IM, et al.
The cost-effectiveness of mycophenolate mofetil as first-line therapy in active lupus nephritis.
*Rheumatology* 2007, e-publ ahead of print ..................................................  39

Wilson ECF, et al.
Age- and gender-specific reference values of estimated GFR in Caucasians: the Nijmegen Biomedical Study.

Yu Ch, et al.

Singh D, et al.
Association of cystatin C and estimated GFR with inflammatory biomarkers: the Heart and Soul Study.

Solez K, et al.
Banff ’05 meeting report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (‘CAN’).
*Am J Transplant* 2007;7:518–526 ..................................................  21

Swaminathan S, et al.
New insights into nephrogenic systemic fibrosis.

Thibaudin D, et al.
TNF A2 and d2 alleles of tumor necrosis factor alpha gene polymorphism are associated with onset/occurrence of idiopathic membranous nephropathy.
*Kidney Int* 2007;71:1–7 ..................................................  8

Tostiavin I, et al.
Renal outcome after ciclosporin-induced nephrotoxicity.

Varghese SA, et al.
Urine biomarkers predict the cause of glomerular disease.

Vincenti F, et al., on behalf of the DIRECT (Diabetes Incidence after Renal Transplantation: Neoral® C2 Monitoring Versus Tacrolimus) Investigators.
Results of an International, Randomized Trial Comparing Glucose Metabolism Disorders and Outcome with Ciclosporine Versus Tacrolimus.
*Am J Transplant* 2007;7:1506–1514 ..................................................  38

Wartha IM, et al.
Increased vascular resistance and not salt retention characterized Cyclosporine A-induced hypertension: Report in an anuric patient.
*Am J Transplant* 2007;7:2042–2046 ..................................................  63

Wetzels JFM, et al.
The cost-effectiveness of mycophenolate mofetil as first-line therapy in active lupus nephritis.
*Rheumatology* 2007, e-publ ahead of print ..................................................  39

Redakce

PF 2008
Všem čtenářům děkujeme za příznu v roce 2007 a těšíme se na shledanou v roce 2008.